A

Addgene

Distributes curated plasmids and vectors

Financial Planning & Analysis Manager

Full-Time
$114k - $130k/yr
Senior, Expert
Bachelor's, MBA
Watertown, MA, USA
HybridAt least three days per week in the Watertown office.
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • A bachelor's degree in Finance, Accounting, Economics, Business, or a related field is required.
  • Five to ten years of progressive experience in FP&A, corporate finance, accounting, or a comparable analytical role is required.
  • Demonstrated ability to use NetSuite for reporting, saved searches, and financial data analysis is required.
  • Advanced Excel skills, including complex formulas, pivot tables, and financial modeling, are required.
  • Strong knowledge of US GAAP and Cost Accounting is required.
  • Proficiency in Google Slides and/or PowerPoint presentations is required.
Responsibilities
  • Lead preparation of the annual operating budget and periodic re-forecasts, partnering with department managers to develop assumptions and track performance against plan.
  • Produce timely monthly and quarterly management reporting, including budget-versus-actual analysis, variance commentary, and key performance indicators.
  • Build, maintain, and improve financial models to support scenario planning, cash flow forecasting, and long-range planning.
  • Use NetSuite to extract financial data, build and maintain saved searches and reports, reconcile results, and support month-end close and reporting processes.
  • Partner with Accounting to ensure the general ledger, chart of accounts, and departmental structure support accurate and meaningful reporting.
  • Analyze revenue, expense, and program trends to identify risks, opportunities, and efficiencies, and translate findings into actionable recommendations.
  • Assist with preparation of materials for Board of Directors and Audit Committee meetings.
  • Support grant, program, and capital budgeting and reporting for a nonprofit environment.
  • Continuously improve FP&A processes, tools, and reporting through automation and better use of systems, including NetSuite and connected planning tools.
  • Prepare ad hoc analyses and presentations for Finance leadership, department heads, and, as needed, the leadership team and Board.
  • Provide financial information to outside auditors and tax advisors.
Desired Qualifications
  • Experience in a nonprofit, mission-driven, or life sciences organization.
  • Hands-on experience with NetSuite Planning & Budgeting (NSPB) or other FP&A/planning software.
  • Familiarity with BI or data visualization tools such as Tableau or Power BI.
  • CPA, CMA, MBA, or progress toward a relevant certification or advanced degree.

About the company

A

Addgene

View
Website

Addgene curates and distributes biological materials to researchers, including a large catalog of plasmids, viral vectors, and recombinant antibodies that are quality-controlled. Materials are contributed by scientists worldwide and shared through a streamlined transfer process plus educational resources to help users work safely and effectively. The organization differentiates itself by prioritizing sharing and community-building, offering a centralized repository and strong support for material transfers and education to enable collaboration. Its goal is to unlock the full potential of research by removing barriers to sharing and fostering a globally connected scientific community.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Cambridge, Massachusetts

Founded

2004

Get referred to Addgene

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 15, 2026 launch expands service revenue across CRISPR, imaging, reporters, and gene expression.
  • March 2026 Plasmidsaurus partnership lowers sequencing bottlenecks as the repository grows 1,000-1,500 monthly.
  • February 2026 hiring Greg Crescenzi accelerates industry partnerships and commercial strategy execution.

What critics are saying

  • Addgene depends on researcher donations; weaker sharing would starve catalog growth within 12 months.
  • Ready-to-pipette DNA commoditizes a core workflow, inviting Thermo Fisher and GenScript price competition.
  • Melina Fan's August 2026 transition raises succession risk if institutional knowledge slips.

What makes Addgene unique

  • Addgene holds 177,170 plasmids from 7,044 labs across 113 countries on September 16, 2026.
  • Addgene sequences, validates, stores, and distributes materials, eliminating lab-to-lab logistics friction.
  • Transfection-Ready DNA pairs NGS verification with ready-to-pipette delivery for 27,000 plasmids.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Disability Insurance
  • Life Insurance
  • Paid Vacation
  • Wellness Program
  • Commuter Benefits
  • Professional Development Budget
  • Pet Insurance

Company News

Associated Press
Sep 15th, 2026
Addgene launches transfection-ready DNA service with 27,000 plasmids for faster research

Addgene has launched its Transfection-Ready DNA service, offering researchers NGS-sequence-verified DNA from its plasmid repository. The service provides purified plasmid DNA ready to add directly to mammalian cell transfection mixes, eliminating the need for bacterial cultivation or in-house miniprep. The service launches with more than 27,000 plasmids available across CRISPR, imaging and reporters, and gene expression. The catalogue will continue expanding alongside Addgene's repository, which grows by 1,000-1,500 plasmids monthly. Each order arrives as purified plasmid DNA at 1.0 µg/µL concentration in 50 µg and 100 µg amounts, meeting a low endotoxin specification of less than 1.0 EU/µg. The service is now available to academic and industry researchers through Addgene's online catalogue.

Addgene
Aug 4th, 2026
Thank you, Melina: A new chapter after 20 years.

Thank you, Melina: A new chapter after 20 years. By Dustin Grinnell As co-founder Melina Fan, PhD, transitions to Chief Scientific Advisor, Addgene reflect on the problem she set out to solve 20 years ago, the community she helped build, and where she and Addgene go next. On August 1, Melina Fan, PhD, stepped into a new role at Addgene. After 20 years, its co-founder is moving out of day-to-day leadership to become its Chief Scientific Advisor, a part-time position focused on science and strategy. It feels like the right moment to say something Addgene don't say often enough: thank you. This isn't goodbye; Melina isn't going far. She'll stay close to the questions she's always cared about, and to the partners she's worked with for years. This is a moment to celebrate what she's built, and to look forward to what's next. | Figure 1: Addgene founders Kenneth Fan, Benjie Chen, and Melina Fan in 2014. | A problem worth solving To understand Melina's impact on Addgene, Addgene has to go back to before Addgene existed. She was a graduate student in cell biology in Bruce Spiegelman's lab, trying to identify the proteins that bound to a transcription factor involved in metabolism. To test whether those interactions were real, she needed plasmids, and getting them was nearly impossible. Of the roughly 20 she requested, about half never arrived. Of the ones that did, many took more than three months, or turned out to be the wrong construct. She could have chalked that up to bad luck. Instead, she asked whether other scientists were running into the same wall. A survey of researchers around Harvard gave a clear answer: people were willing to share, but the logistics were getting in the way. A sample might sit lost in a freezer years after the person who made it had moved on. The details of how it was made might exist only in a notebook on a shelf. And shipping a material across borders was its own project entirely, one that had nothing to do with the science a lab actually wanted to do. Melina already had a postdoc offer at Stanford, and since high school, she'd pictured a future in research. But the problem she'd run into stuck with her. The professor she was set to work with gave her something rare. She could take a year to chase the idea, with the reassurance that the opportunity would still be there if things didn't pan out. That gave her room to take a risk. Shortly after finishing her PhD, she founded Addgene. What Melina built at Addgene Melina didn't build Addgene alone, and she's the first to say so. The founding team was three people, each bringing something different. Melina brought the biology. Her husband, Benjie Chen, a computer scientist, built the first systems and the original website. Her brother, Kenneth Fan, provided the business and finance chops needed to stand up a real organization. The early days were modest. Addgene started in about 800 square feet of half-empty space Harvard wasn't using in Kendall Square, with shared equipment, furniture pulled from hallways, and reliable freezers with backup power and alarms. From day one, every sample was barcoded and tracked, and every deposit stored in triplicate - two copies at Addgene, one backup in Rockville, Maryland - so a single point of failure could never mean losing a sample forever. In the early days, building Addgene's collection meant going lab to lab in person. They drove from one institution to the next, digging through notebooks and freezers to track down samples that labs often couldn't find on their own. The legal side was its own hurdle. Material transfer agreements, or MTAs, which govern how shared materials can be used, were handled on paper and could take months to sign, so they rebuilt the process. Depositors signed once, requesters signed electronically, and a standard agreement handled the rest. What used to take three months could now take as little as a few minutes. Then there was money. As a nonprofit, Addgene couldn't raise venture capital, and its early grant applications to the NIH were all turned down. Funds were running low. The turning point came at a dinner in Cambridge, where a friend's father, a university professor, pointed the team toward two viral packaging plasmids he predicted would become the most requested materials in the collection. He was right. Every year since, including last year, those same two plasmids have remained the most requested in the collection. | Figure 2: Addgene's first viral vector shipment in 2016. | A shift bigger than any one repository Ask Melina what she's most proud of, and the first answer is the shift in mindset Addgene helped spark. When the organization began, researchers were technically required to share their materials once they published. In practice, few did. And when they tried, it was often a hassle. Today, depositing your materials when you publish is the norm. Addgene wasn't alone in making that shift - other open-science efforts came up around the same time - but together, they helped make openness the default. As sharing caught on, Addgene's reach grew with it. Addgene has now shared materials nearly 2.5 million times with researchers in 113 countries. When CRISPR arrived, Addgene was already established enough to help the community share those tools immediately. Years later, when COVID-19 hit and demand for those same tools surged, Addgene helped researchers get access when rapid collaboration mattered most. And because depositors had chosen to share from the beginning, that work also proved something important: sharing research materials and building a business around them don't have to be at odds. The people and the community When it comes to building and growing the organization and its culture, Melina gives the credit to the Addgenies themselves: talented, driven, and always looking out for one another. And above all, she points to the depositors. Their inventions, their willingness to share, their generosity in answering questions, writing guides, and helping other scientists succeed with their materials; that's what makes the collection what it is. Addgene, she says, is just the platform that helps carry forward how good these scientists already are. That instinct to keep the scientist at the center of every decision is exactly what its Executive Director, Chonnettia Jones, PhD, came back to in her own note to Melina: "For more than two decades, you never faltered in keeping the scientist at the heart of every decision - not as a value written on a wall, but as a daily practice, visible in everything Addgene does and every standard we hold ourselves to. That is your legacy, and it belongs to every Addgenie who has carried it forward." - Chonnettia Jones, PhD, Executive Director, Addgene | Figure 3: Melina receives Addgene's Blue Flame Award in 2019. | The right time for a new chapter So why step back now? For Melina, it comes down to confidence in the organization, and in the people running it. Twenty years is a big chapter, and Addgene is in good hands. She also sees value in a fresh perspective, especially on the science side, where the field moves fast and new ideas benefit from people who are closer to the bench than she's been able to be lately. To her, this is the right moment for new voices to lead. What comes next In her advisory role, Melina will focus on science and strategy, staying close to the questions she cares about most. She also wants to keep hearing from the scientific community. Addgene exists because of a problem she once had at the bench, and she wants to know what problems researchers still run into today that Addgene might be able to help solve. As for what comes after that, Melina is in no rush. She's giving herself room to figure out what's next, and she wants it to be work that means something to her. Looking ahead One analogy Melina keeps coming back to is that Addgene is a bit like a kid who's grown up - educated, capable, ready to take its own steps in the world. Success, to her, means Addgene can thrive without depending on any one person, and can find its own way forward. She's optimistic about where science is headed, and about Addgene's part in it, providing a dependable infrastructure that helps researchers across the life sciences do work they couldn't do otherwise. Looking ahead, she hopes Addgene keeps making things easier for scientists and stays ready for whatever the scientific community needs solved next. Thank you, Melina, for seeing the frustration so many scientists had quietly accepted and treating it like a problem worth solving. Thank you for 20 years of building a resource, a community, and a place where people care for each other while doing work that matters. Addgene is grateful for what you've given Addgene, and Addgene is glad you won't be far. Subscribe to the Addgene blog

Yahoo Finance
Feb 26th, 2026
Greg Crescenzi joins Addgene as VP of global commercial strategy and partnerships

Addgene has appointed Greg Crescenzi as Vice President of Global Commercial Strategy and Partnerships. He will lead business development efforts and execute commercial strategy across global customer segments as the organisation expands its offerings to industry partners. Crescenzi brings over 30 years of life sciences experience, having served as CEO of Nirrin Technologies, CCO of Kytopen, and held senior leadership roles at Cytiva, BD Biosciences, Pall Corporation and Millipore. He holds an MBA from Boston University and a BS in Chemical Engineering from Tufts University. Addgene operates a repository of over 170,000 plasmids, viral vectors and antibodies for researchers worldwide. The organisation aims to accelerate scientific discovery by providing expertly curated, quality-controlled research tools to both academic and industry customers.

The Manila Times
Feb 26th, 2026
Addgene Appoints Greg Crescenzi as Vice President of Global Commercial Strategy and Partnerships

Addgene appoints Greg Crescenzi as Vice President of Global Commercial Strategy and Partnerships. By GlobeNewswire February 26, 2026 WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) - Addgene, an organization committed to accelerating discovery and innovation by providing a vast catalog of expertly curated and quality-controlled research tools developed by researchers, today announced the appointment of Greg Crescenzi as Vice President of Global Commercial Strategy and Partnerships. With his leadership in commercializing industry-first products and technologies, Crescenzi will drive the organization's business development efforts while executing a disciplined, mission-aligned commercial strategy across global customer segments. For over twenty years, Addgene has promoted scientific sharing by building a repository where scientists can deposit validated, high-quality research materials, with more than 170,000 plasmids, viral vectors, and antibodies now available to researchers around the world. "This is an exciting time to join Addgene, as the organization continues to expand its tools available to industry partners," said Crescenzi. "The scientific community has long trusted Addgene to power their research in academic labs across the globe, and now they can continue to leverage a growing selection of our services in their role as industry innovators. I'm grateful to join a team committed to accelerating science and discovery - from academic to startup labs and beyond." Greg Crescenzi is a life sciences executive with over 30 years of experience driving innovation and growth across the biopharmaceutical industry. Prior to Addgene, he was a Strategic Advisor, partnering with organizations ranging from early-stage startups to Fortune 500 companies to accelerate commercialization and achieve transformational outcomes. Greg has served as CEO of Nirrin Technologies, CCO of Kytopen, and held senior leadership roles at Cytiva (GE Healthcare Life Sciences), BD Biosciences, Pall Corporation, and Millipore. He is known for commercializing industry-first products, scaling businesses, and building high-performance teams. Greg holds an MBA with High Honors from Boston University and a BS in Chemical Engineering from Tufts University. "We are thrilled to welcome Greg to the Addgene team as we continue to broaden access to high-quality research tools that power scientific progress," said Chonnettia Jones, PhD, President and Executive Director at Addgene. "His leadership will be a key asset in our efforts to forge mission-aligned strategic partnerships that drive organizational growth, while scaling our offerings to academic and industry customers alike." About Addgene Addgene is a purpose-driven organization committed to accelerating discovery and innovation by helping scientists conduct experiments with greater ease, speed, and reproducibility. We are pioneers in scientific sharing, providing a vast catalog of expertly curated and quality-controlled plasmids developed by researchers around the world. We offer viral vector and recombinant antibody services built from the same trusted approach. Our dedicated team reduces barriers to scientific progress by facilitating material transfers and providing world-class educational resources. At Addgene, we care about building a globally connected scientific community collaborating and sharing seamlessly to unlock the full potential of research. For more information, visit https://www.addgene.org. Media Contact: Michael Falcone Pearl Street Partners (617) 990-6712

Addgene
Feb 5th, 2026
Strengthening Foundations: Reflections on 2025 and What's Ahead for 2026

Strengthening foundations: reflections on 2025 and what's ahead for 2026. As 2025 closed, Addgene, Inc. received a request that perfectly embodies why Addgene exists: a researcher in Laos needed a unique set of plasmids to advance their research. Thanks to five different labs across the U.S. who deposited their plasmids with Addgene to share with the rest of the world, the plasmids arrived in the researcher's lab in under two weeks, making Laos the 112th country that Addgene, Inc. support. This story is a vivid example of how the global scientific community's generosity makes it possible for researchers worldwide to access the tools they need, accelerating scientific progress across borders. This past year, Addgene, Inc. welcomed over 500 new depositing labs who entrusted Addgene, Inc. with their research materials. Addgene materials contributed to 9,000 publications in 2025 alone, each representing questions answered, hypotheses tested, and knowledge advanced. Behind every publication is another great story, like researchers in India using Addgene-shared tools to develop new vaccine approaches against emerging viral threats, or scientists in Colombia leveraging plasmids from Addgene's CRISPR collection to uncover how key plant defense genes protect crops from devastating disease. The collective willingness of researchers to share their materials enables countless breakthroughs, ensures that scientific inquiry builds on prior discovery, and advances new knowledge. Turning Researcher Feedback into Real Improvements In a world where funding cycles shift, regulations change, and supply chains strain, Addgene remains a constant. Behind the scenes, Addgene, Inc. continue to refine its processes to enhance efficiency and quality - both fundamental to maintaining the reliability you depend on. In 2025, Addgene, Inc. focused on what researchers needed most: reliable access to quality materials and associated data to be able to use them effectively. In response to the constant evolution of scientific tools and computational approaches, Addgene, Inc. ensured that access to reliable plasmid information keeps pace. Opening its plasmid data through the Developer's Portal means that researchers can integrate Addgene's rich data into workflows and unlock new tools and discoveries. Addgene, Inc. also responded to your feedback. Many of you asked for a smaller size for its on-demand viral vector packaging service to better match experiment needs and budgets, and Addgene, Inc. made that happen. Others needed a faster way to find plasmids with specific sequences, so Addgene, Inc. introduced Search by Sequence to help you locate exactly the right tools for your experiments. Still others told Addgene, Inc. about the need for more open-source, highly characterized recombinant antibodies, so Addgene, Inc. is partnering with leading neuroscience and antibody experts to expand this collection. Stronger Partnerships, Broader Impact As Addgene, Inc. move into 2026, its focus turns to strengthening the networks that make science possible. Addgene, Inc. is expanding its collections strategically and forging new partnerships that will bring more tools to more researchers in academia - but also for researchers in industry, as Addgene, Inc. make its collections more comprehensively accessible to scientific entrepreneurs. From emerging technologies to underrepresented research areas, Addgene, Inc. is working to ensure that when scientists need materials, Addgene can help. In the coming year, you'll see Addgene, Inc. focus even more intently on efficiency without compromising the quality that defines Addgene. Many of these improvements will happen quietly in the background, but you'll feel their impact in faster turnaround times and more reliable service. Addgene, Inc. also have some exciting developments on the horizon. New partnerships are taking shape. Novel products are in development. And Addgene, Inc.'ll be refreshing its look to reflect how Addgene, Inc. has evolved while staying true to its mission. Stay tuned! Addgene, Inc. is eager to share more details in the months ahead. Looking Ahead Together As I reflect on 2025 and step into 2026, I'm inspired by the resilience and generosity of the global scientific community. Whether you're depositing plasmids, ordering viral vectors, or exploring its educational resources, you're an essential part of a worldwide community helping scientists access the tools they need to advance knowledge, fuel collaborations, and drive breakthroughs. None of this progress happens in isolation. It's made possible by a shared commitment to openness, collaboration, and supporting one another's work. Sign up for its newsletter to be the first to know about new collections, services, and resources designed to support your research. Thank you for letting Addgene, Inc. be part of your story, and for being such an important part of ours. Addgene, Inc. is grateful to move into 2026 alongside you, strengthening the foundations of science together. References and Resources Ñañez, J., Valdes, S., Cruz Gallego, M., Rebolledo, M. C., Lorieux, M., Alvarez, M. F., & Chavarriaga, P. (2025). Revealing the role of the AGO4 gene against rice hoja blanca virus: from transformation to protein structure. Frontiers in plant science, 16, 1517321. https://doi.org/10.3389/fpls.2025.1517321 Singh, O. N., Berry, U., Joshi, G., Asuru, T. R., Chandrasekar, K., Narayanan, S., Srivastava, P., Tiwari, M., Chattopadhyay, S., Mehdi, F., Panda, B. N., Nayak, D., Mani, S., Shrivastava, T., Batra, G., Ranjith-Kumar, C. T., Guchhait, P., & Surjit, M. (2025). Comparison of immunogenicity and protection efficacy of self-amplifying and circular mRNA vaccines against SARS-CoV-2. iScience, 28(10), 113498. https://doi.org/10.1016/j.isci.2025.113498